In this uncertain situation, randomized controlled studies in selected cirrhotic patients or compensated alcoholic liver fibrosis from different research groups demonstrated that candesartan, another angiotensin receptor blocking agent, not only lowered the hepatic venous pressure gradient, but also diminished liver fibrosis with a reduction in hyaluronic acid, TGF-β1 and extracellular matrix proteins (Kim et al., 2012; Debernardi-Venon et al., 2007). The gene discussed is TGFB1; the disease is Hepatic fibrosis.